Association of viral variant and vaccination status with the occurrence of symptoms compatible with post-acute sequelae after primary SARS-CoV-2 infection

Christian R. Kahlert<sup>1,2</sup> MD, Carol Strahm<sup>1</sup> MD, Sabine Güsewell<sup>1</sup> PhD, Alexia Cusini<sup>3</sup> MD, Angela Brucher<sup>4</sup> MD, Stephan Goppel<sup>5</sup> MD, J. Carsten Möller<sup>6</sup> MD, Manuela Ortner<sup>7</sup>, Markus Ruetti<sup>8</sup> MD, Reto Stocker<sup>9</sup> MD, Danielle Vuichard-Gysin<sup>10,11</sup> MD MSc, Ulrike Besold<sup>12</sup> MD, Allison McGeer<sup>13</sup> MD MSc, Lorenz Risch<sup>14,15,16</sup> MD PhD, Andrée Friedl<sup>17</sup> MD, Matthias Schlegel<sup>1</sup> MD, Pietro Vernazza<sup>1</sup> MD, Stefan P. Kuster<sup>1\*</sup> MD MSc, Philipp Kohler<sup>1\*</sup> MD MSc, SURPRISE Study Group

# Author affiliations:

<sup>1</sup> Cantonal Hospital St Gallen, Division of Infectious Diseases and Hospital Epidemiology, St Gallen, Switzerland

<sup>2</sup>Children's Hospital of Eastern Switzerland, Department of Infectious Diseases and Hospital

Epidemiology, St. Gallen, Switzerland

<sup>3</sup>Cantonal Hospital of Grisons, Division of Infectious Diseases, Chur, Switzerland

<sup>4</sup> Psychiatry Services of the Canton of St. Gallen (South), Switzerland

<sup>5</sup> Psychiatry Services of the Canton of St. Gallen (North), Switzerland

<sup>6</sup>Center for Neurological Rehabilitation, Zihlschlacht, Switzerland

<sup>7</sup> Rheintal Werdenberg Sarganserland Hospital Group, Grabs, Switzerland

<sup>8</sup> Fuerstenland Toggenburg Hospital Group, Wil, Switzerland

<sup>9</sup> Hirslanden Clinic, Zurich, Switzerland

<sup>10</sup> Thurgau Hospital Group, Division of Infectious Diseases and Hospital Epidemiology,

Muensterlingen, Switzerland

<sup>11</sup> Swiss National Centre for Infection Prevention (Swissnoso), Berne, Switzerland

<sup>12</sup> Geriatric Clinic St. Gallen, St. Gallen, Switzerland

<sup>13</sup> Sinai Health System, Toronto, Canada NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

<sup>14</sup> Labormedizinisches Zentrum Dr Risch Ostschweiz AG, Buchs, Switzerland

<sup>15</sup> Private Universität im Fürstentum Liechtenstein, Triesen, Liechtenstein

<sup>16</sup> Center of Laboratory Medicine, University Institute of Clinical Chemistry, University of Bern,

Inselspital, Bern, Switzerland

<sup>17</sup> Cantonal Hospital Baden, Division of Infectious Diseases and Hospital Epidemiology, Baden,

Switzerland

Keywords: SARS-CoV-2, health care workers, viral variants, omicron, post-acute, post-covid condition

# **Corresponding author**

Philipp Kohler

Cantonal Hospital St. Gallen, Division of Infectious Diseases and Hospital Epidemiology

Rorschacherstrasse 95

9007 St. Gallen, Switzerland

E-Mail: philipp.kohler@kssg.ch, Phone: +41 71 494 1148

# 1 ABSTRACT

| 2  | Importance: Disentangling the effects of different SARS-CoV-2 variants and of vaccination on       |
|----|--|
| 3  | the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and              |
| 4  | potentially reduce the future burden of PASC.  |
| 5  |  |
| 6  | Objective: To determine the association of primary SARS-CoV-2 infection on the frequency of        |
| 7  | PASC symptoms by viral variant and vaccination status.   |
| 8  |  |
| 9  | Design: Cross-sectional questionnaire and SARS-CoV-2 serology (May/June 2022) performed            |
| 10 | within a prospective healthcare worker cohort (SURPRISE study).                                    |
| 11 |  |
| 12 | Setting: Multicenter study in nine healthcare networks from North-Eastern Switzerland.             |
| 13 |  |
| 14 | Participants: Volunteer sample of healthcare workers (HCW) from participating institutions. Of     |
| 15 | approximately 20'000 eligible participants, 3'870 registered for the cohort and 2'912 were         |
| 16 | included in this analysis.   |
| 17 |  |
| 18 | Exposures: SARS-CoV-2 infection documented by positive nasopharyngeal swab (>4 weeks               |
| 19 | ago), stratified by viral variant and vaccination status at time of infection, compared to absence |
| 20 | of documented infection (no positive swab, negative serology).                                     |
| 21 |  |
| 22 | Main Outcome: Sum score of eighteen self-reported PASC symptoms.                                   |
| 23 |  |
| 24 | Results: Among 2'912 participants (median age 44 years, 81.3% female), SARS-CoV-2                  |
| 25 | infection was reported by 1'685 (55.9%) participants, thereof 315 (18.7%) during Wild-type, 288    |
| 26 | (17.1%) during Alpha/Delta, and 1'082 (64.2%) during Omicron circulation. Mean symptom             |
| 27 | number in previously infected participants significantly exceeded that of uninfected controls      |
| 28 | (0.39), but decreased with recency of the viral variant: 1.12 (p<0.001) for Wild-type (median      |

| 29 | time since infection 18.5 months), 0.67 (p<0.001) for Alpha/Delta (6.6 months), and 0.52         |
|----|--|
| 30 | (p=0.005) for Omicron BA.1 (3.1 months) infected participants. After Omicron BA.1 infection, the |
| 31 | mean symptom score was 0.49 (p=0.30) for those with ≥3 prior vaccinations and 0.71 (p=0.028)     |
| 32 | with 1-2 previous vaccinations compared to 0.36 for unvaccinated individuals. Adjusting for      |
| 33 | confounders, Wild-type (adjusted risk ratio [aRR] 2.81, 95% confidence interval [CI] 2.08-3.83)  |
| 34 | and Alpha/Delta infection (aRR 1.93, 95% CI 1.10-3.46) showed significant associations with      |
| 35 | the outcome, whereas Omicron BA.1 infection (aRR 1.29, 95% CI 0.69–2.43) and vaccination         |
| 36 | before infection (aRR 1.27, 95% CI 0.82–1.94) did not.   |
| 37 |  |
| 38 | Conclusions and Relevance: Previous infection with pre-Omicron variants was the strongest        |
| 39 | risk factor for reporting PASC symptoms in this HCW cohort. A definite influence of prior        |
| 40 | vaccination on the prevention of PASC after Omicron BA.1 infection was not measurable.           |

## 42 INTRODUCTION

43 Early in the current severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, 44 it has become apparent that not all patients fully recover from Coronavirus Disease 2019 45 (COVID-19), but have persistent physical and mental health symptoms<sup>1,2</sup>. As SARS-CoV-2 46 continues to evolve and its variants spread across the globe, post-acute sequelae after SARS-47 CoV-2 (PASC) or Long COVID represents a significant challenge to healthcare systems<sup>3</sup>. The 48 estimates on the frequency of Long COVID vary greatly, depending on definitions used and time 49 elapsed since infection<sup>4,5</sup>. The currently most common SARS-CoV-2 variant, Omicron, spreads 50 even more efficiently but seems less pathogenic in acute disease, at least in a population with 51 robust immunity<sup>6</sup>. As severity of acute infection has directly been associated with the risk of developing PASC<sup>7,8</sup>, this condition might be less common after Omicron infection compared to 52 53 previous variants. Indeed, previous data show that compared to the Delta variant, after COVID-19 with Omicron, the risk for PASC is reduced by around 50%<sup>9</sup>. However, in this study, 54 55 comparison with Alpha and the Wild-type was not possible; also, the study lacked a control 56 group, which is crucial to correctly attribute these often non-specific symptoms to COVID-19<sup>10</sup>. 57 Decreasing prevalence of PASC over time has also been reported from an Italian healthcare 58 worker (HCW) cohort. In addition, the authors suggested that PASC develops less frequently in 59 individuals who are vaccinated against SARS-CoV-2 before being infected<sup>11</sup>. Again, this study 60 did not include a control group and infections occurring in the Delta and Omicron period were 61 not evaluated separately. In this study, we aimed to compare symptoms compatible with PASC between HCW after 62 63 infection with different SARS-CoV-2 variants and uninfected seronegative controls. Also, we 64 assessed the impact of mRNA COVID-19 vaccine on symptoms compatible with PASC.

## 66 METHODS

#### 67 Setting and participants

The study was approved by the ethics committee of Eastern Switzerland. Written informed consent was obtained from participants. The observational multicenter study included volunteer HCW from eight healthcare networks in Northern/Eastern Switzerland<sup>12</sup>. The study population consisted mostly of participants from a previous HCW cohort, which had been launched in July/August 2020. In addition, new participants were recruited for the current study (**Figure S1**).

75 Participants from the original cohort were prospectively followed between July/August 2020 and

76 May/June 2022 with electronic questionnaires capturing SARS-CoV-2 positive swabs and

vaccinations; also, repetitive SARS-CoV-2 serologies were performed (Figure S2)<sup>13</sup>.

In May/June 2022, the cross-sectional study was performed including SARS-CoV-2 serology

and an electronic questionnaire, asking about personal characteristics and risk factors, such as

80 comorbidities, medications, household members, work type, exposure to COVID-19 patients,

81 and the presence of PASC symptoms Participants also reported dates of previous SARS-CoV-

82 2-positive nasopharyngeal swabs and vaccinations. Participants with multiple positive swabs

and those with a first positive swab within 4 weeks or a vaccination within 1 week prior to the

84 questionnaire were excluded.

85

# 86 SARS-CoV-2 diagnostics

87 Participants were asked to get tested for SARS-CoV-2 in case of compatible symptoms,

88 according to national recommendations. Depending on the participating institution, SARS-CoV-

2 was detected by rapid antigen test or polymerase chain reaction. Self-reported

nasopharyngeal swabs results were validated as previously described<sup>13</sup>. In May/June 2022,

91 participants were serologically screened for anti-spike (anti-S) and anti-nucleocapsid (anti-N)

92 antibodies, to identify pauci-/asymptomatically infected individuals<sup>12</sup>. The Roche Elecsys (Roche

93 Diagnostics, Rotkreuz, Switzerland) electro-chemiluminescence immunoassay was used<sup>14</sup>.

94

## 95 Definition of viral variant and vaccination status

96 The viral variant infecting a participant was inferred from the time of first positive swab according to sequencing data from Northeastern Switzerland<sup>15</sup>: Wild-type infections (February 97 98 2020 to January 2021); Alpha variant (February to June 2021); Delta variant (July to December 99 2021); Omicron variant (B.1.1.529.1; BA.1) (January to June 2022) (Figure S2). Infections 100 during the Alpha period were merged with those during the Delta period due to the small 101 number of Alpha infections. Participants without any previous positive SARS-CoV-2 swab and 102 with negative anti-N in May/June 2022 were considered as uninfected controls. Those without 103 positive SARS-CoV-2 swab but positive anti-N were excluded from further analyses. 104 Vaccination status was assessed based on self-reported participant data. Over 99% of

105 vaccinated participants indicated receipt of either the mRNA-1273 or the BNT162b2 vaccine.

106

107 Outcomes

108 Participants were given a list of symptoms compatible with PASC and were asked to check

109 those present at time of the questionnaire for more than 7 days but not before the pandemic.

110 Symptoms included loss of smell/taste, shortness of breath, chest pain, hair loss, brain fog,

111 tiredness/weakness, skin rash, muscle/limb pain, joint point, headache, nausea/anorexia,

dizziness, stomachache, diarrhea, burnout/exhaustion, fever >38° Celsius or feverish feeling,

113 chills, and cough. The main outcome was the total number of these 18 symptoms; individual

114 symptoms were also analyzed.

As additional outcomes, participants answered a 9-item fatigue score (Fatigue Severity Scale, FSS)<sup>16</sup>, reported their self-rated health (SRH) on a 5-point scale (from "poor" to "excellent")<sup>17</sup>, and indicated whether they think they would suffer from Long COVID (yes vs. no). For those answering the latter question with yes, the severity of Long COVID was assessed using the Post-COVID-19 Functional Status Scale (PCFS), a 5-point scale from "no restrictions in daily live" to "severe restrictions" (**Table S1**)<sup>18,19</sup>.

### 122 Statistical analysis

123 We used descriptive statistics to compare baseline characteristics between those infected with 124 the Wild-type virus, the Alpha/Delta variant, the Omicron BA.1 variant, and uninfected controls. 125 For the main analysis, mean PASC symptom scores were compared between each of the 126 infected groups and controls, respectively, using univariable negative-binomial models. Mean 127 sum scores and 95% likelihood ratio confidence intervals (CI) were derived from models without 128 intercept. The significance of differences was evaluated using Wald tests on coefficients of 129 models with uninfected controls as intercept. The same analyses were performed separately by 130 vaccination status: unvaccinated, vaccinated after infection (controls with any vaccination date), 131 and vaccinated before infection with  $\geq 1$  vaccine dose (controls with any vaccination date). 132 Second, the frequency of individual symptoms was compared between each of the infected 133 groups and controls, respectively, using logistic regression. This analysis was performed 134 separately for those unvaccinated at time of infection (ie, never vaccinated individuals or 135 vaccination after infection) and those with ≥1 vaccine dose before infection. Controls were 136 uninfected individuals without and with any vaccination, respectively. 137 Third, we compared the mean symptom score between boosted (>3 vaccinations at least 7 days 138 before infection) and non-boosted (1-2 vaccinations) compared to unvaccinated (but also 139 infected) participants using negative-binomial models. This analysis was restricted to 140 participants infected in the Delta (without the Alpha group) and Omicron period, because 141 booster vaccination was not available before.

142

#### 143 Multivariable analysis

To assess the independent impact of viral variant and vaccination status on symptom number, we used a multivariable negative-binomial regression model. Variables previously found to be associated with the occurrence of Long COVID were included in the model (**Table S1**)<sup>7,20</sup>. Rate ratios (RR) derived from model coefficients and corresponding 95% CI are shown as forest plots; P-values were obtained from Wald tests.

# 150 Sensitivity analysis

- 151 To minimize the risk of incorrect group assignment due to undetected earlier SARS-CoV-2
- 152 infection, we re-ran the main analysis and the multivariable analysis including only individuals
- 153 with previous serology data available and excluding those with any positive anti-N before the
- 154 first positive SARS-CoV-2 swab or before the survey (for controls) (**Figure S1**).
- 155

# 156 Analysis of additional outcomes

- 157 Additional outcomes were analyzed between each of the infected group and controls. For this
- 158 purpose, we used a negative-binomial model (FSS), logistic regression (self-classification of
- 159 having Long COVID), and proportional-odds logistic regression (distribution of SRH ratings and
- 160 PCFS). These analyses were not stratified by vaccination status. R statistical software Version
- 161 4.0.2 was used for statistical analysis; two-sided p-values of <.05 were considered significant.
- 162 This report follows the STROBE reporting guideline for observational studies<sup>21</sup>.

## 164 **RESULTS**

- 165 Study population and SARS-CoV-2 infections
- 166 Of approximately 19'600 eligible study participants, 3'870 answered the questionnaire in
- 167 May/June 2022 and 2'912 were included in the analysis (Figure S1). Median age was 44 years
- and 81.3% were women. SARS-CoV-2 infection was reported by 1'685 (57.9%) participants,
- thereof 315 (18.7%) during the Wild-type, 288 (17.1%) during the Alpha/Delta, and 1'082
- 170 (64.2%) during the Omicron period. Median time since infection was 18.3 months (interquartile
- 171 range [IQR] 17.5-19.2) for Wild-type, 6.5 (IQR 6.0-9-0) for Alpha/Delta, and 3.1 (IQR 2.6-4.0) for
- 172 Omicron BA.1 infections. The group of uninfected controls consisted of 1'227 individuals. Of the
- 173 2'912 individuals, 2'570 reported baseline characteristics (**Table 1**).
- 174

## 175 PASC symptoms and viral variant

- 176 The 2'912 participants reported a mean of 0.55 symptoms (including those without symptoms).
- 177 Mean symptom number in the three groups of previously infected participants significantly
- 178 exceeded that of uninfected controls (0.39), but decreased with recency of the viral variant: 1.12
- 179 (p<0.001) for Wild-type, 0.67 (p<0.001) for Alpha/Delta, and 0.52 (p=0.005) for Omicron BA.1
- 180 infected participants (Figure 1a). Similar decreasing trends across viral variants were observed
- 181 for unvaccinated participants (**Figure 1b**), for those with vaccination before or after infection
- 182 (Figure 1c), and also in the sensitivity analysis, although sample size was small in individual
- 183 subgroups (**Figure S3**).

At least one symptom was reported by 695 (23.9%) participants, and this share was significantly raised after infection: 38.7% for Wild-type infected participants (p<0.001), 31.6% for Alpha/Delta (p=0.001), 23.8% for Omicron BA.1 (p=0.001), compared to 18.3% for uninfected individuals. The most commonly reported symptoms overall were tiredness/weakness with a frequency of 14.7% in infected and 9.4% in uninfected participants. Symptoms consistently associated with

- 189 SARS-CoV-2 infection across all variants were loss of smell/taste and hair loss for unvaccinated
- 190 (Figure S4), and loss of smell/taste and brain fog for vaccinated participants (Figure S5).

#### 192 PASC symptoms and vaccination status

Among participants infected during the Delta period, vaccinated individuals (+/- booster)
reported on average fewer symptoms than unvaccinated participants; however, the differences
were not statistically significant. After Omicron BA.1 infection, the mean reported symptom
number was 0.49 (p=0.30) for those with ≥3 prior vaccinations and 0.71 (p=0.028) for those with
1-2 previous vaccinations compared to 0.36 for unvaccinated individuals (Figure 2). *Multivariable analysis*In multivariable analysis, infection with the Wild-type virus (adjusted rate ratio [aRR] 2.81, 95%

201 CI 2.08–3.83) and with the Alpha/Delta variant (aRR 1.93, 95% CI 1.10–3.46) were positively 202 associated with the number of symptoms reported, whereas infection during the Omicron period 203 (aRR 1.29, 95% CI 0.69–2.43) and vaccination before infection (aRR 1.27, 95% CI 0.82–1.94) 204 were not. Other variables associated with the outcome were body mass index (BMI) >30 m/kg<sup>2</sup> 205 (aRR 1.43, 95% CI 1.08–1.92), having a pre-existing comorbidity (RR 1.35, 95% CI 1.11–1.65), 206 being on any medication (aRR 1.49, 95% CI 1.20–1.86) and cumulative COVID-19 patient 207 contact (aRR 1.11, 95% CI 1.01–1.21) (Figure 3, Table S2). Effect sizes for viral variants 208 increased slightly in sensitivity analysis, whereas other co-variables, except being on any 209 medication, were no longer associated with the outcome (Figure S6).

210

#### 211 Additional outcomes

Both the FSS and the SRH were highest or lowest, respectively, for those after Wild-type
infection, while no difference was observed between those with Alpha/Delta or Omicron BA.1
infection and controls (**Table 2**). The percentage of participants who considered themselves
suffering from Long COVID was substantially higher after Wild-type (17.1%, p<0.001),</li>
Alpha/Delta (10.4%, p<0.001), and Omicron BA.1 infection (4.8%, p<0.001) compared to</li>
controls (0.9%). For those suffering from Long COVID, functional impairment in daily live as per

218 the PCFS score was similar between groups.

## 220 **DISCUSSION**

Within a well-defined HCW population, we show that the most decisive risk factor for reporting symptoms compatible with PASC is the viral variant causing the primary infection. Participants after Wild-type SARS-CoV-2 and Alpha/Delta infections reported the highest numbers even 18 and 6 months after infection, respectively. In contrast, those at 3 months after Omicron BA.1 infection are only minimally affected compared to uninfected controls. SARS-CoV-2 vaccination including receipt of booster vaccine before Omicron BA.1 infection was not associated with less PASC symptoms.

228 The viral variant was the most important risk factor associated with the presence of PASC

symptoms, even after adjusting for co-variables typically associated with Long COVID, such as

age, sex, BMI, and vaccination status. Individuals after Wild-type reported significantly more

231 PASC symptoms, had a higher fatigue score and a lower SRH than uninfected controls. These

findings are particularly worrying considering that Wild-type infections occurred a median of 18

233 months before this survey. Few studies have reported such a long duration of PASC.

234 Persistence of symptoms for 12 months have been reported by several others, both in

hospitalized and non-hospitalized populations<sup>22–24</sup>. One study demonstrated the persistence of

memory problems at 18 months after mild SARS-CoV-2 infection and another showed that 38%

of infected patients still reported symptoms at 23 months after infection<sup>25,26</sup>. In addition, some

authors have suggested that loss of smell/taste, which was one of the symptoms showing a

clear association with PASC in our study, might potentially be a permanent sequela after

240 COVID-19<sup>27</sup>. Further research aiming at mitigating the PASC burden in those infected early on

in the pandemic is urgently needed.

237

The frequency of Long COVID after infection with the Omicron variant has been reported to be 5% at  $\geq$ 4 weeks after infection, which is about half compared to the Delta variant<sup>9</sup>. Comparing people infected with Omicron vs. previous variants, 5 vs. 55% reported  $\geq$ 1 PASC symptom in another study<sup>28</sup>. However, both studies have not included a non-infected control group, which allows to better interpret the significance of these findings. In our study, participants after Omicron BA.1 infection still reported more symptoms than uninfected controls. However, we

248 found that many symptoms typically associated with PASC, such as fatigue, exhaustion or 249 muscle/limb pain,<sup>1</sup> were only slightly or not at all more common after Omicron BA.1 infection 250 compared to uninfected controls. On the other hand, the high prevalence of some of these 251 symptoms in uninfected individuals highlights the importance to also consider other causes, 252 besides COVID-19, underlying these symptoms. This particularly includes conditions such as 253 chronic fatigue syndrome/myalgic encephalomyelitis, which have been shown to be often related to other viral infections<sup>29–31</sup>. Importantly, in contrast to participants after Wild-type 254 255 infection, FSS and SRH were not any different between Omicron BA.1 infected and uninfected 256 controls.

257 Our data further suggest that vaccination with SARS-CoV-2 mRNA vaccines prior to Omicron 258 BA.1 infection does not lower the risk of PASC. This is in contrast to previous studies from the pre-Omicron era, which showed a benefit of vaccination against PASC<sup>32,33</sup>. In addition, an Italian 259 260 study found that vaccination before infection during the Delta/Omicron period was indeed 261 associated with decreased risk for long COVID<sup>11</sup>. The discrepancy can be explained by the fact 262 that in this study, infections during the Delta and Omicron period were pooled; hence, the effect 263 of previous vaccination on Long COVID could have been mainly driven by Delta infections. In 264 line with this hypothesis, our data suggest that previous vaccination might have been protective 265 against PASC after Delta, although results were not statistically significant due to the small number of cases. In contrast, previous vaccination was clearly not associated with a reduction 266 267 of PASC symptoms after Omicron BA.1 infection despite the large number of cases. Further 268 studies are needed to confirm our finding.

Important strengths of our study are the clearly defined infection and vaccine status of every
individual study participant as well as the relatively large share of hitherto unvaccinated
participants. This enabled us to adequately disentangle the effects of viral variant and of SARSCoV-2 vaccination on the occurrence of PASC symptoms, a task which is increasingly
becoming unrealizable due to high vaccination and infection rates, particularly in HCW<sup>34</sup>. The
probably most important strength is the inclusion of a non-infected control group, which many
previous studies on Long COVID have lacked<sup>10</sup>. A Dutch study recently reported the frequency

276 of PASC symptoms in infected vs. non-infected individuals, and attributed these symptoms in 277 12.7% of cases to COVID-19. Yet, the study was performed before circulation of the Delta and 278 Omicron variants; furthermore, no SARS-CoV-2 serology was performed which would allow to also capture asymptomatic infections<sup>35</sup>. We relied on anti-N negativity to exclude previous 279 280 infection. We acknowledge that this definition may have missed a certain proportion of infected 281 individuals due to lack of seroconversion or waning antibody titers over time<sup>14</sup>. In a post-hoc 282 analysis, we found that 11.7% of those with negative anti-N reported indeed a positive swab. By 283 considering both criteria, anti-N negativity and lack of positive swab, we think that our approach 284 of defining an uninfected control group is reasonable. Furthermore, results of the sensitivity 285 analysis, which also considered previous serology results and excluded those with waning 286 immunity over time, largely confirmed our main findings.

287 Our study has further limitations. First, definition of viral variants was based on population data 288 and not on individual sequencing data. This might have led to misclassifications of viral variants 289 in any direction and therefore to an underestimation of the observed differences. Second, the 290 choice of our outcome definition can be debated. The large number of symptoms and the less 291 strict time criterion (symptoms had to be present at least for 7 days) compared to other studies 292 might have led to an overestimation of PASC prevalence. Third, we cannot exclude that vaccine 293 hesitancy could be associated with the way people perceive and/or report physical and mental 294 health symptoms, which would distort the comparability between vaccinated and unvaccinated 295 participants. Fourth, our data lack generalizability both in terms of study population as well as of 296 viral variants. We cannot exclude that Omicron BA.1 infections occurring in the elderly or more 297 comorbid populations, where acute infection might manifest itself more severely, might confer 298 an increased risk of PASC; also, our results are not necessarily applicable to newer Omicron 299 variants.

To conclude, these data suggest that in a HCW population of predominantly young, healthy Caucasian females, individuals infected with the Wild-type, and less so with the Alpha/Delta variants, still report symptoms compatible with PASC after a median of 18 and 6 months, respectively, whereas the burden at 3 months after Omicron BA.1 infection is considerably

- 304 lower. Vaccination prior to Omicron BA.1 infection was not associated with less PASC
- 305 symptoms. Future research should primarily address the needs of individuals infected early on
- 306 in the pandemic, whereas in individuals suffering from symptoms compatible with PASC after
- 307 Omicron BA.1 infection, other aetiologies besides COVID-19 should be actively sought.

## 309 Acknowledgments

310 We also thank the participants of the SURPRISE study and the members of the study group (in 311 alphabetical order): Ulrike Besold, MD (Geriatric Clinic St. Gallen), Angela Brucher, MD 312 (Psychiatry Services South, St. Gallen), Alexia Cusini, MD (Cantonal Hospital Graubünden), 313 Thomas Egger (Cantonal Hospital St. Gallen), Andrée Friedl, MD (Cantonal Hospital Baden), 314 Stephan Goppel, MD (Psychiatry Services North, St. Gallen), Fabian Grässli, MSc (Cantonal 315 Hospital St. Gallen), Christian R. Kahlert, MD (Children's Hospital of Eastern Switzerland, St. 316 Gallen), Joelle Keller (Hirslanden Clinic Zurich), Simone Kessler (Cantonal Hospital St. Gallen), 317 Philipp Kohler, MD MSc (Cantonal Hospital St. Gallen), Stefan P. Kuster, MD MSc (Cantonal 318 Hospital St. Gallen), Onicio Leal, PhD (University of Zurich), Eva Lemmenmeier, MD (Clienia 319 Littenheid), Allison McGeer, MD MSc (Mount Sinai Hospital, Toronto), Dorette Meier Kleeb, MD 320 (Cantonal Hospital Baden), J. Carsten Möller, MD (Clinic Zihlschlacht), Maja F. Müller 321 (Hirslanden Clinic Zurich), Vaxhid Musa (Cantonal Hospital St. Gallen), Manuela Ortner 322 (Rheintal Werdenberg Sarganserland Hospital Group, Grabs), Philip Rieder, PhD (Hirslanden 323 Clinic Zurich), Lorenz Risch, MD PhD (Laboratory Risch Buchs), Markus Ruetti, MD 324 (Fuerstenland Toggenburg Hospital Group Wil), Matthias Schlegel, MD (Cantonal Hospital St. 325 Gallen), Hans-Ruedi Schmid, PhD (Cantonal Hospital Baden), Reto Stocker, MD (Hirslanden 326 Clinic Zurich), Pietro Vernazza, MD (Cantonal Hospital St, Gallen), Matthias von Kietzell MD 327 (Clinic Stephanshorn St. Gallen), Danielle Vuichard-Gysin, MD MSc (Thurgau Hospital Group 328 Muensterlingen), and Benedikt Wiggli, MD (Cantonal Hospital Baden).

329

330 This work was supported by the Swiss National Sciences Foundation (grant number

331 31CA30\_196544; grant number PZ00P3\_179919 to PK), the Federal Office of Public Health 332 (grant number 20.008218/421-28/1), the Health Department of the Canton of St. Gallen, and the 333 research fund of the Cantonal Hospital of St. Gallen. Funding institutions did not have any role 334 in design and conduct of the study; collection, management, analysis, and interpretation of the 335 data; preparation, review, or approval of the manuscript; and decision to submit the manuscript 336 for publication.

337 The authors have no other conflicts of interest to declare.

#### 338 REFERENCES

- 339 1. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-340 615. doi:10.1038/s41591-021-01283-z
- 341 2. Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ. 342 2022;376:e068993. doi:10.1136/bmj-2021-068993
- 343 3. Phillips S, Williams MA. Confronting Our Next National Health Disaster — Long-Haul Covid. N Engl J 344 Med. 2021;385(7):577-579. doi:10.1056/NEJMp2109285
- 345 4. Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent 346 Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw Open. 347 2021;4(5):e2111417. doi:10.1001/jamanetworkopen.2021.11417
- 348 Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of Individuals 5. 349 With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic 350 COVID-19 in 2020 and 2021. JAMA. Published online October 10, 2022. 351 doi:10.1001/jama.2022.18931
- 352 6 Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and 353 death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a 354 cohort study. Lancet Lond Engl. 2022;399(10332):1303-1312. doi:10.1016/S0140-6736(22)00462-7
- 355 Strahm C, Seneghini M, Güsewell S, et al. Symptoms compatible with long-COVID in healthcare 7. 356 workers with and without SARS-CoV-2 infection - results of a prospective multicenter cohort. Clin 357 Infect Dis Off Publ Infect Dis Soc Am. Published online January 28, 2022:ciac054. doi:10.1093/cid/ciac054 358
- 359 8 Bahmer T, Borzikowsky C, Lieb W, et al. Severity, predictors and clinical correlates of post-COVID 360 syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. 361 EClinicalMedicine. 2022;51:101549. doi:10.1016/j.eclinm.2022.101549
- 362 9. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta 363 versus omicron variants of SARS-CoV-2. The Lancet. 2022;399(10343):2263-2264. 364 doi:10.1016/S0140-6736(22)00941-2
- 365 10. Amin-Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for 366 characterizing long COVID. Nat Med. 2021;27(7):1129-1130. doi:10.1038/s41591-021-01402-w
- 367 11. Azzolini E, Levi R, Sarti R, et al. Association Between BNT162b2 Vaccination and Long COVID After 368 Infections Not Requiring Hospitalization in Health Care Workers. JAMA. 2022;328(7):676-678. 369 doi:10.1001/jama.2022.11691
- 370 12. Kahlert CR, Persi R, Güsewell S, et al. Non-occupational and occupational factors associated with 371 specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study. Clin 372 Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2021;27(9):1336-1344. 373 doi:10.1016/j.cmi.2021.05.014
- 374 13. Kohler P, Güsewell S, Seneghini M, et al. Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort 375 study. BMC Med. 2021;19(1):270. doi:10.1186/s12916-021-02144-9 376
- 377 14. Baron RC, Risch L, Weber M, et al. Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study. Clin Chem Lab Med. Published online 378 379 August 31, 2020. doi:10.1515/cclm-2020-0978
- 380 15. Federal Office of Public Health. Virus variants overview. Last accessed April 1st 2021. 381 https://www.covid19.admin.ch/en/epidemiologic/virus-variants

medRxiv preprint doi: https://doi.org/10.1101/2022.10.21.22281349; this version posted October 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: Application to
   Patients With Multiple Sclerosis and Systemic Lupus Erythematosus. *Arch Neurol.* 1989;46(10):1121 1123. doi:10.1001/archneur.1989.00520460115022
- 17. Idler EL, Benyamini Y. Self-rated health and mortality: a review of twenty-seven community studies. J
   Health Soc Behav. 1997;38(1):21-37.
- 18. Klok FA, Boon GJAM, Barco S, et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. *Eur Respir J*. 2020;56(1):2001494.
  doi:10.1183/13993003.01494-2020
- Machado FVC, Meys R, Delbressine JM, et al. Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19. *Health Qual Life Outcomes*. 2021;19(1):40. doi:10.1186/s12955-021-01691-2
- 393 20. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med.* 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y
- 395 21. STROBE, Strengthening the reporting of observational studies in epidemiology. https://www.strobe 396 statement.org
- 22. Pazukhina E, Andreeva M, Spiridonova E, et al. Prevalence and risk factors of post-COVID-19
  condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort
  study in Moscow (StopCOVID). *BMC Med.* 2022;20(1):244. doi:10.1186/s12916-022-02448-4
- 400 23. Seeßle J, Waterboer T, Hippchen T, et al. Persistent Symptoms in Adult Patients 1 Year After
  401 Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2022;74(7):1191-1198. doi:10.1093/cid/ciab611
- 403 24. Haddad A, Janda A, Renk H, et al. Long COVID symptoms in exposed and infected children,
  404 adolescents and their parents one year after SARS-CoV-2 infection: A prospective observational
  405 cohort study. *EBioMedicine*. 2022;84:104245. doi:10.1016/j.ebiom.2022.104245
- 406
   407
   407
   408
   408
   408
   409
   408
   409
   409
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
   400
- 409 26. Helmsdal G, Hanusson KD, Kristiansen MF, et al. Long COVID in the Long Run—23-Month Follow410 up Study of Persistent Symptoms. *Open Forum Infect Dis.* 2022;9(7):ofac270.
  411 doi:10.1093/ofid/ofac270
- 412 27. Mendes Paranhos AC, Nazareth Dias ÁR, Machado da Silva LC, et al. Sociodemographic
  413 Characteristics and Comorbidities of Patients With Long COVID and Persistent Olfactory
  414 Dysfunction. JAMA Netw Open. 2022;5(9):e2230637. doi:10.1001/jamanetworkopen.2022.30637
- 415 28. Morioka S, Tsuzuki S, Suzuki M, et al. Post COVID-19 condition of the Omicron variant of SARS416 CoV-2. J Infect Chemother Off J Jpn Soc Chemother. 2022;28(11):1546-1551.
  417 doi:10.1016/j.jiac.2022.08.007
- 418 29. Magnus P, Gunnes N, Tveito K, et al. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. *Vaccine*. 2015;33(46):6173-6177. doi:10.1016/j.vaccine.2015.10.018
- 421 30. Petersen I, Thomas JM, Hamilton WT, White PD. Risk and predictors of fatigue after infectious
  422 mononucleosis in a large primary-care cohort. *QJM Mon J Assoc Physicians*. 2006;99(1):49-55.
  423 doi:10.1093/qjmed/hci149
- 424 31. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. *Nat Med.* 425 2022;28(5):911-923. doi:10.1038/s41591-022-01810-6

medRxiv preprint doi: https://doi.org/10.1101/2022.10.21.22281349; this version posted October 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 426 32. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 427 2022;28(7):1461-1467. doi:10.1038/s41591-022-01840-0
- 428 33. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-429 CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, 430 nested, case-control study. Lancet Infect Dis. 2022;22(1):43-55. doi:10.1016/S1473-3099(21)00460-431 6
- 432 34. Adriaenssens N, Scholtes B, Bruyndonckx R, et al. Prevalence, incidence and longevity of antibodies 433 against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study 434 with 12 months of follow-up. BMJ Open. 2022;12(9):e065897. doi:10.1136/bmjopen-2022-065897
- 435 35. Ballering AV, Zon SKR van, Hartman TC olde, Rosmalen JGM. Persistence of somatic symptoms 436 after COVID-19 in the Netherlands: an observational cohort study. The Lancet. 437 2022;400(10350):452-461. doi:10.1016/S0140-6736(22)01214-4

#### **TABLES** 439

#### 440 Table 1. Characteristics of 2'570 participants answering the study questionnaire by time of first

#### 441 positive SARS-CoV-2 swab.

| Baseline characteristics   | Wild-type<br>infection<br>n = 283 | Alpha/Delta<br>infection<br>n = 268 | Omicron<br>infection<br>n = 963 | No infection $n = 1056$ | <i>p</i> -<br>value <sup>b</sup> |
|--|-----------------------------------|-------------------------------------|---------------------------------|-------------------------|----------------------------------|
| Age (years, median and IQR)  |                                   |                                     |                                 |                         | <0.00                            |
| Sex (male vs. female)  | 44 (33-54)                        | 42 (32-49)                          | 42 (34-52)                      | 48 (37-56)              | 1                                |
| $\mathbf{DM}(\mathbf{x}, \mathbf{y}) = \mathbf{z}_{1}^{2} \mathbf{x}_{1}^{2} \mathbf{x}_{2}^{2} \mathbf{x}_{1}^{2} \mathbf{x}_{2}^{2} \mathbf{x}_{1}^{2} \mathbf{x}_{2}^{2} \mathbf{x}_{2}^$ | 54 (19.1%)                        | 47 (17.5%)                          | 173 (18.0%)                     | 206 (19.5%)             | 0.787                            |
| BIVII (>30 VS. ≤30 kg/m²)  | 40 (14.1%)                        | 23 (8.6%)                           | 97 (10.1%)                      | 134 (12.7%)             | 0.055                            |
| Ethnicity (Caucasian)  | 275 (97.2%)                       | 259 (96.6%)                         | 946 (98.2%)                     | 1024<br>(97.0%)         | 0.442                            |
| Child ≤ 6 years in household   |                                   | (,                                  | 0.00 (00.270)                   | (011070)                | <0.00                            |
|  | 36 (12.7%)                        | 36 (13.4%)                          | 150 (15.6%)                     | 91 (8.6%)               | 1                                |
|  | 143 (50.5%)                       | 116 (43.3%)                         | 467 (48.5%)                     | 514 (48.7%)             | 0.343                            |
| Pollen allergy   | 86 (30.4%)                        | 77 (28.7%)                          | 322 (33.4%)                     | 331 (31.3%)             | 0.438                            |
| Other comorbidities  | 86 (30.4%)                        | 58 (21.6%)                          | 254 (26.4%)                     | 299 (28.3%)             | 0.085                            |
| Any medication   | 97 (34.3%)                        | 66 (24.6%)                          | 271 (28.1%)                     | 335 (31.7%)             | 0.026                            |
| Active smoking   | 41 (14.5%)                        | 44 (16.4%)                          | 154 (16.0%)                     | 200 (18.9%)             | 0.186                            |
| Alcohol (>1 drink per week)  | 113 (39.9%)                       | 103 (38.4%)                         | 424 (44.0%)                     | 419 (39.7%)             | 0.089                            |
| Profession   | - ()                              |                                     | (                               |                         | <0.00                            |
| Nurse  | 175 (61 8%)                       | 149 (55 6%)                         | 459 (47 7%)                     | 476 (45 1%)             | I                                |
| Physician  | 173(01.070)                       |                                     | 433 (47.776)                    | 470 (45.1%)             |                                  |
| Other  | 27 (9.5%)                         | 23 (0.0%)                           | 127 (13.2%)                     | 163 (15.4%)             |                                  |
| Cumulative contact duration to   | 81 (28.6%)                        | 96 (35.8%)                          | 377 (39.1%)                     | 417 (39.5%)             |                                  |
| COVID-19 patients (minutes,<br>median and IQR)   | 400 (30-2250)                     | 285 (1-<br>1200)                    | 150 (1-<br>1000)                | 130 (1-750)             | <0.00<br>1                       |
| Intensive care   | 52 (18.4%)                        | 32 (11.9%)                          | 133 (13.8%)                     | 140 (13.3%)             | 0.113                            |
| Full-time work (>0.8 FTE)  | 147 (51.9%)                       | 128 (47.8%)                         | 475 (49.3%)                     | 561 (53.1%)             | 0.239                            |
| Vaccination <sup>a</sup>   |                                   |                                     |                                 |                         | <0.00<br>1                       |
| before infection   | 0 (0.0%)                          | 165 (61.6%)                         | 876 (91.0%)                     | 0 (0.0%)                |                                  |
| after or without infection   | 255 (90.1%)                       | 35 (13.1%)                          | 3 (0.3%)                        | (96.8%)                 |                                  |
| no vaccination   | 28 (9.9%)                         | 68 (25.4%)                          | 84 (8.7%)                       | 34 (3.2%)               |                                  |

IQR, Interquartile Range; BMI, Body Mass Index; FTE, Full Time Equivalent <sup>a</sup> Note that numbers are slightly lower than in Figure 1 because 342 individuals only reported data on infections and vaccinations, but no further data. <sup>b</sup> Global test for the significance of group differences. Kruskal-Wallis test for numeric variables (age, cumulative patient contact

446 duration) and Chi-squared test for categorical variables (all others).

#### Table 2. Results of additional outcomes by time of first infection (or no infection) among 2'912 447

#### 448 participants.

# 449

|   | Wild-type          | Alpha/Delta        | Omicron            | No                       |
|---|--------------------|--------------------|--------------------|--------------------------|
|   | infection          | infection          | infection          | infection                |
|   | <i>n</i> = 315     | n = 288            | <i>n</i> = 1082    | n = 1227                 |
| Fatigue severity score, FSS (mean) <sup>a</sup>                     | 22.5**             | 20.4 <sup>ns</sup> | 20.4 <sup>ns</sup> | 20.5 <sup>ref</sup>      |
| Self-reported health, SRH<br>(mean) <sup>a</sup>                    | 4.18*              | 4.36*              | 4.30 <sup>ns</sup> | 4.30 <sup>ref</sup>      |
| 1 (Very bad)  | 0.6%               | 1.0%               | 0.5%               | 0.3%                     |
| 2 (Bad)   | 0.3%               | 0.3%               | 0.7%               | 0.4%                     |
| 3 (Average)   | 14.3%              | 7.6%               | 8.1%               | 8.0%                     |
| 4 (Good)  | 49.5%              | 43.4%              | 49.5%              | 51.4%                    |
| 5 (Very good)   | 35.2%              | 47.6%              | 41.1%              | 39.9%                    |
| Having long COVID (n [%])ª  | 54 (17.1%)***      | 30 (10.4%)***      | 52 (4.8%)***       | 11 (0.9%) <sup>ref</sup> |
| PCFS (mean) <sup>a</sup>  | 2.25 <sup>ns</sup> | 2.14*              | 2.32 <sup>ns</sup> | 2.73 <sup>ref</sup>      |
| 1 (No restrictions) <sup>b</sup>                                    | 14.8%              | 36.7%              | 17.3%              | 0%                       |
| 2 (Negligible restrictions) <sup>b</sup>                            | 53.7%              | 33.3%              | 44.2%              | 45.5%                    |
| 3 (Restrictions, able to fulfill daily activities) <sup>b</sup>     | 24.1%              | 13.3%              | 26.9%              | 36.4%                    |
| 4 (Restrictions, not able to fulfill daily activities) <sup>b</sup> | 7.4%               | 16.7%              | 11.5 %             | 18.2%                    |
| 5 (Severe restrictions) <sup>b</sup>                                | 0%                 | 0%                 | 0%                 | 0%                       |

450 451 <sup>a</sup> Asterisks indicate statistically significant differences in outcome distribution between each infected group and uninfected controls, as given by p-values from Wald tests on the coefficients of a negative binomial model for FSS, proportional-odds logistic regression for SRH and PCFS, and ordinary logistic regression for having long COVID (\*\*\*, p < 0.001; \*\*, p < 0.01; \*, p < 0.05; ns, p ≥ 0.05, ref, 453 454 reference group).

<sup>b</sup> Percentages refer to the number of participants with self-reported long COVID

PCFS, Post-COVID-19 Functional Status Scale (assessed only by those with self-reported long COVID)

## 457 **FIGURES**

- 458 Figure 1. Cross-sectional analysis of May/June 2022. Means and 95% confidence intervals of
- 459 post-acute sequelae of SARS-CoV-2 symptom score by viral variant and vaccination status.
- 460 Asterisks above bars indicate statistical significance in reference to uninfected participants with
- 461 same vaccination status, respectively, as obtained through Wald tests on coefficients of
- 462 negative binomial models with uninfected participants as reference group (\*\*\*, p < 0.001; \*\*, p <
- 463 0.01; \*, p < 0.05; ns, p ≥ 0.05). N at the bottom of the bars designate number of participants.
- 464 Note: there were no vaccinations before Wild-type infection and only three individuals
- 465 vaccinated after Omicron BA.1 infection (not shown in panel C).
- 466
- 467

| 468 | Figure 2. Means and 95%      | confidence intervals of | post-acute sed | uelae of SARS-CoV-2 |
|-----|------------------------------|-------------------------|----------------|---------------------|
| -00 | i iguite z. Micario and 3070 |                         | posi-acuic scy |                     |

- 469 symptom score in relation to number of vaccine doses received before positive swab. Left:
- 470 Participants after infection in Delta period (1 July 1<sup>st</sup> to December 31<sup>th</sup> 2021). Right: Participants
- 471 after infection in Omicron BA.1 period (January 1<sup>st</sup> to June 30<sup>th</sup> 2022). Asterisks above bars
- 472 indicate statistical significance in reference to unvaccinated participants infected in the same
- 473 period, respectively, as obtained through Wald tests on coefficients of negative binomial models

474 with group "none" as reference (\*, p < 0.05; <sup>ns</sup>,  $p \ge 0.05$ ).

475 476 477

478

479

480

481

- 483 Figure 3. Results of multivariable negative binomial model regarding number of symptoms
- 484 compatible with post-acute sequelae of SARS-CoV-2. Predictors positively associated with
- 485 symptom number (i.e. 95% confidence interval for rate ratio entirely above 1) are highlighted in
- 486 red. For numeric values of point estimates and 95% confidence intervals see Table S3.

487

A All participants **B** Unvaccinated participants C Vaccinated participants 2.0<sub>1</sub> 2.0 \*\* 2.0 Wild Type Alpha/Delta Omicron BA.1 Number of symptoms \*\*\* ns \*\*\* 1.5 1.5 1.5 no infection 1.0⊧ 1.0 1.0 \*\*\* \*\* ns 0.5 0.5 0.5 315 288 1082 1227 55 980 99 35 183 1172 0.0 0.0 0.0 vaccinated vaccinated after infection before infection



